Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s health and wellness, today announced the launch of direct sales of the GENEVEVE treatment to physicians and healthcare providers in Canada. Delivered by the internationally patented Viveve® System, the GENEVEVE treatment improves sexual function by treating the vaginal introitus, after vaginal childbirth.
“We are excited to offer Canadian physicians and patients Viveve’s clinically proven cryogen cooled monopolar radiofrequency technology for the treatment of vaginal laxity, a common medical condition experienced by millions of women, that impacts their sexual satisfaction and quality of life,” said Patricia Scheller, chief executive officer of Viveve. “Women now have options and they no longer need to just accept bothersome symptoms. This safe, sound, and comfortable treatment provides women and their doctors an innovative therapeutic solution, backed by rigorous clinical science,” she continued.
Educational materials and informational sessions that address the value and clinically proven benefits of the GENEVEVE treatment are available throughout Canada for healthcare providers, and their female patients. Additional information and the calendar of key physician events are available at www.ViveveCanada.com.